Valuation : Sanofi

Market Cap 92.44B 107B 86.75B 79.37B 148B 10,157B 149B 1,026B 400B 5,190B 403B 395B 16,716B P/E 2026 *
12.3x
P/E 2027 * 10.7x
Enterprise Value 104B 121B 97.5B 89.21B 166B 11,415B 168B 1,153B 449B 5,834B 453B 444B 18,788B EV / Sales 2026 *
2.18x
EV / Sales 2027 * 1.98x
Free-Float
88.34%
Yield 2026 *
5.51%
Yield 2027 * 5.83%
Manager TitleAgeSince
Chief Executive Officer 65 30/04/2026
Director of Finance/CFO 64 31/03/2024
Chief Tech/Sci/R&D Officer - 31/08/2026
Director TitleAgeSince
Director/Board Member 61 29/04/2019
Director/Board Member 57 27/04/2020
Director/Board Member 65 27/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
-8.92%-.--% - - 107B
-0.07%-1.32%+57.29%+107.91% 1,034B
+0.97%+4.51%+56.04%+72.86% 663B
-0.28%+1.00%+23.07%+78.47% 462B
+2.09%-2.06%+32.28%+38.37% 344B
0.00%+5.36%+27.40%+47.50% 307B
+1.42%+0.26%-0.52%+13.62% 251B
+0.11%+1.53%+56.31%+74.67% 239B
-0.03%+2.13%-17.30%-53.99% 207B
+0.82%+0.95%+32.99%+99.93% 186B
Average -0.25%-0.70%+29.73%+53.26% 410.37B
Weighted average by Cap. +0.32%-0.84%+38.58%+68.40%

Financials

2026 *2027 *
Net sales 47.68B 55.42B 44.75B 40.94B 76.41B 5,239B 77.02B 529B 206B 2,677B 208B 204B 8,622B 50.81B 59.05B 47.68B 43.62B 81.42B 5,582B 82.07B 564B 220B 2,853B 222B 217B 9,188B
Net income 7.91B 9.19B 7.42B 6.79B 12.68B 869B 12.78B 87.82B 34.2B 444B 34.53B 33.77B 1,431B 9.24B 10.74B 8.67B 7.94B 14.81B 1,016B 14.93B 103B 39.96B 519B 40.34B 39.46B 1,672B
Net Debt 11.46B 13.32B 10.75B 9.84B 18.36B 1,259B 18.51B 127B 49.53B 643B 50B 48.91B 2,072B 8.3B 9.65B 7.79B 7.13B 13.31B 912B 13.41B 92.18B 35.9B 466B 36.24B 35.45B 1,502B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
77.16EUR
Average target price
94.28EUR
Spread / Average Target
+22.19%

Quarterly revenue - Rate of surprise